Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhodiola extract + saffron extract
- Development stage
- Unknown
- Lead developer
- PiLeJe
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
A botanical dietary supplement combining extracts of *Rhodiola rosea* L. (root) and *Crocus sativus* L. (saffron stigma). Developed by PiLeJe Laboratoire and marketed in France since 2015, it is intended for the management of mild to moderate depression. The product contains 154 mg of rhodiola extract and 15 mg of saffron extract per tablet, with a recommended dose of two tablets per day. Clinical data from observational studies indicate significant improvements in Hamilton Rating Scale for Depression (HAM-D) scores and anxiety symptoms, though it is classified as a dietary supplement rather than an approved pharmaceutical drug.
- Brand names
- Phytostandard de Rhodiole et Safran
- Other names
- rhodiola and saffron combinationRhodiola rosea and Crocus sativus combination
02
Targets
MAOA (Monoamine oxidase A)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on rhodiola extract + saffron extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhodiola extract + saffron extract.